Time to first occurrence of any of the components of the composite endpoint - acute interstitial lung disease (ILD) exacerbation, first hospitalisation for respiratory cause, or death (whichever occurred first) - is reported as the number of participants who experienced any of these events during the trial.

Acute exacerbation of ILD describes an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality with all of the following: Acute worsening or development of dyspnea typically with less than 1 month duration, computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILD, and deterioration not fully explained by cardiac failure or fluid overload.

If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute ILD exacerbation, hospitalization, death.

Full Analysis Set (FAS): This patient set included all randomised patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analysed as their randomised treatment group.

Time to first acute ILD exacerbation or death over the duration of the trial is reported as the number of patients who experienced either event. Acute exacerbation of ILD describes an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality with all of the following: Acute worsening or development of dyspnea typically with less than 1 month duration, computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILD, and deterioration not fully explained by cardiac failure or fluid overload.

If more than one component occurred on the same day, the patient was counted under the first event according to the following hierarchy: acute IPF exacerbation followed by death.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group.

Time to hospitalisation for respiratory cause or death over the duration of the trial is reported as the number of participants who experienced either event. Hospitalizations due to respiratory causes were recorded on a specific non-elective hospitalization CRF page. This page captured the hospitalization date, confirmation of a respiratory cause, and the primary admission diagnosis. Time to death was based either on the date of death on the adverse event (AE) report for patients with AEs leading to death or was based on the information from the vital status assessment.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group.

The absolute change from baseline in forced vital capacity (FVC) in milliliters [mL] at Week 52 is reported. The absolute change from baseline in FVC was analyzed by a restricted maximum likelihood (REML)-based mixed model with repeated measurements (MMRM) comparing the change from baseline in FVC at Week 52 between treatment groups. The analysis included the fixed, categorical effects of treatment, baseline intake of antifibrotic (AF) treatment, and baseline High-resolution Computed Tomography (HRCT) pattern at each visit, as well as the fixed continuous effects of baseline FVC value at each visit. Visits were treated as a repeated measure with an unstructured covariance structure used to model within-patient measurements.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group. Only patients with baseline measurement and at least one post-baseline measurement were included.

Time to death over the duration of the trial is reported as the number of participants who died.

Time to death was based either on the date of death on the AE report for patients with AEs leading to death or based on the information from the vital status assessment.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group.

Absolute change from baseline in forced vital capacity (FVC) percent (%) predicted at Week 52 is reported.

Analysis was based on a Mixed Model for Repeated Measures (MMRM), with fixed, categorical effects of treatment at each visit, baseline antifibrotic therapy at each visit, baseline HRCT pattern at each visit, the fixed continuous effects of baseline FVC [% pred] at each visit and unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were used as covariates.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group.

Only participants with baseline measurement and at least one post-baseline measurement were included.

The time to absolute decline of more than 10% from baseline in forced vital capacity (FVC) percent predicted, or death, over the duration of the trial is reported as the number of participants who experienced either event.

If multiple components occurred on the day of first event, then the patient was only counted in the first component based on the following hierarchy: absolute decline in FVC % predicted of > 10% followed by death.

Full Analysis Set (FAS): This patient set includes all randomised patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analysed as their randomised treatment group.

The absolute change from baseline in Diffusing Capacity of the Lungs for Carbon Monoxide percent predicted (corrected for hemoglobin, Hb) at Week 52 is reported.. Analysis was based on a Mixed Model for Repeated Measures (MMRM), with fixed, categorical effects of treatment at each visit, baseline antifibrotic therapy at each visit, baseline HRCT pattern at each visit, the fixed continuous effects of baseline DLCO [% pred] at each visit and unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were used as covariates.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group.

Only participants with baseline measurement and at least one post-baseline measurement were included.

Time to absolute decline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) percentage predicted by more than 15% from baseline or death, measured over the duration of the trial is reported as the number of participants who experienced either event. The Predicted DLCO value was corrected for hemoglobin (Hb). If more than one component occurred on the same day, the patient was counted under the first event according to the hierarchy: Absolute decline in DLCO % predicted of > 15%, followed by Death.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group.

The absolute change from baseline in Living with Pulmonary Fibrosis (L-PF) Symptoms Dyspnea domain score at Week 52 is reported. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnoea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment.

This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, baseline HRCT pattern, and fixed continuous effect of baseline L-PF dyspnea score at each visit, with an unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were covariates.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group.

Only participants with baseline measurement and at least one post-baseline measurement were included.

The absolute change from baseline in the L-PF Cough domain score at Week 52 is reported. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment.

This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, baseline HRCT pattern, and fixed continuous effect of baseline L-PF dyspnea score at each visit, with an unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were covariates.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group.

Only participants with baseline measurement and at least one post-baseline measurement were included.

The absolute change from baseline in the L-PF Fatigue domain score at Week 52 is reported. The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44-item tool consisting of two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: Dyspnea, Cough, and Fatigue, as well as a Total Symptoms score. Scoring is based on the mean of item ratings within each domain, multiplied by 100. Scores range from 0 to 100, with higher scores indicating greater impairment.

This endpoint was analyzed using a Mixed Model for Repeated Measures (MMRM). The model included fixed effects for treatment, baseline antifibrotic therapy, and baseline HRCT pattern at each visit, and fixed continuous effect of baseline L-PF Fatigue score at each visit, with an unstructured covariance for repeated measures. Baseline antifibrotic therapy and HRCT pattern as entered in the CRF pages were covariates.

Full Analysis Set (FAS): This patient set included all randomized patients who received at least one dose of study drug. The FAS was used for baseline demographics and characteristics, protocol deviations, and all efficacy analyses, in which patients were analyzed as their randomized treatment group.

Only participants with baseline measurement and at least one post-baseline measurement were included.